SCHEMBL13675955

SCHEMBL13675955

CC(C)(C)c1ccc(CCC(=O)Nc2ccc3cn[nH]c3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.55
ALDH1A1 P00352 4/20 0.53
P2RX7 Q99572 1/20 0.53
MAPT P10636 2/20 0.51
MCHR1 Q99705 7/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CLK2 P49760 2/20 0.50
CLK4 Q9HAZ1 2/20 0.50
PRKX P51817 1/20 0.50
CAMK2D Q13557 1/20 0.50
PKN2 Q16513 1/20 0.50
STK17A Q9UEE5 1/20 0.50
MAP4K4 O95819 1/20 0.49
DYRK1A Q13627 1/20 0.49
SRPK1 Q96SB4 1/20 0.49
SYK P43405 1/20 0.49
BTK Q06187 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675977 0.82 TRPV1 (0.60) TRPV1MCHR1BTK
SCHEMBL22590395 0.81 P2RX7 (0.58) ALDH1A1P2RX7MAPTNPSR1CLK2
SCHEMBL6762504 0.80 P2RX7 (0.62) ALDH1A1P2RX7MAPTNPSR1CLK2
SCHEMBL13675972 0.79 TRPV1 (0.62) TRPV1ALDH1A1MAPTMCHR1CYP1A2
SCHEMBL13675971 0.78 TRPV1 (0.58) TRPV1ALDH1A1MAPTMCHR1NPSR1
SCHEMBL13675980 0.78 TRPV1 (0.55) TRPV1MCHR1
SCHEMBL23084085 0.77 RECQL (0.66) ALDH1A1P2RX7MAPTNPSR1CLK2
SCHEMBL13675992 0.77 TRPV1 (0.57) TRPV1MAPTMCHR1
SCHEMBL5640026 0.77 MEN1 (0.62) P2RX7CLK2CLK4PRKXPKN2
SCHEMBL23084047 0.77 HPGD (0.63) ALDH1A1P2RX7MAPTNPSR1CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 TRPV1 1/4885ALDH1A1 3238/4885P2RX7 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.